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Introduction
　The body surface is covered with various types of epi-
thelia, which are constantly exposed to a variety of mi-
crobial challenges.  The epithelium functions as a me-
chanical and protective barrier to bacterial infection. 
Oral mucosa consisting of stratified squamous 
epithelium is a highly permeable tissue with regional 
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Abstract : Human β-defensin（hBD）2 is an epithelial antimicrobial peptide.  We studied single-nucleotide 
polymorphisms in the gene of hBD-2 in a Japanese population, and estimated the effect of a polymorphism in 
the promoter/enhancer region on the transcriptional activity.  By sequencing the hBD-2 gene of 50 unrelated 
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activity than did the variant-type（A）.  The SNP at position－1029 may inﬂ uence the hBD-2 expression and 
cause genetic variations in susceptibility to infectious diseases.
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variation1.  Although inﬂ ammatory cells such as neutro-
phils inﬁ ltrate into oral epithelium as an antimicrobial 
response to severe bacterial infection, the inﬁ ltration is 
not universally observed under normal conditions. 
Thus, the β-defensin family of antimicrobial peptides, 
which are produced constantly in oral epithelium, may 
contribute to the prevention of bacterial infection under 
normal conditions2-4. 
　Defensins are small, cationic antimicrobial peptides 
that can kill a wide variety of Gram-positive and Gram-
negative bacteria and fungi, as well as enveloped virus-
es such as herpes simplex.  Defensins are divided into 
the subfamilies of α-, β- and θ-defensins2-9.  In hu-
mans, 31 types of human β-defensins（hBDs）were re-
cently discovered by a computational search strategy10. 
hBD-1～ -3 are well documented by their expression 
patterns and their antimicrobial activity.  They are 
mainly expressed by epithelial cells of many organs, in-
cluding skin, lung, kidney, pancreas, uterus, eye, sali-
vary duct, nasal and oral epithelia.  hBD-1 is constitu-
tively expressed by epithelial cells, whereas hBD-2 and 
3 are expressed upon stimulation with pro-inﬂ ammato-
ry cytokines, such as IL-1β, TNFα and IFNγ.  The an-
timicrobial activity of hBD-1 and -2 is impaired by high 
salt concentrations, whereas that of hBD-3 is indepen-
dent of salt concentration.  Among hBD-1～ -3, hBD-2 
is most effective in killing Gram-negative bacteria2-8. 
Gram-negative bacteria such as Actinobacillus 
actinomycetemcomitance and Porphyromonas gingivalis 
are often involved in periodontal disease11.  Thus, hBD-2 
may have a protective role in the oral epithelium 
against periodontal disease.  We have previously shown 
the different expression levels of hBDs among oral epi-
thelial cell lines12 and have recently shown that the ex-
pression levels of hBDs vary over a wide range in a Jap-
anese population13, suggesting that there may be 
genetic variations in hBDs. 
　In the present study, we identiﬁ ed 11 single-nucleo-
tide polymorphisms in hBD-2 genes, including promoter 
and exon regions, in a Japanese population and investi-
gated how the polymorphism in promoter sites affects 
the transcriptional activity.
Materials and methods
Samples
　All experimental procedures, including DNA sampling 
and sequencing were done with the approval of the Eth-
ics Committee on Human Genetic Research in the 
Health Sciences University of Hokkaido.  Fifty unrelat-
ed Japanese individuals were sampled, and DNA was 
extracted from swab samples of the buccal mucosa
（QIAamp DNA Mini Kit, QIAGEN）. 
DNA ampliﬁ cation and sequence
　The hBD-2 gene（reference NCBI AF040153）up to 
position －1500 was ampliﬁ ed from each DNA sample in 
multiple overlapping segments by PCR.  The speciﬁ c 
primers and their conditions used to amplify the hBD-2 
genes are shown in Table 1.  The DNAs were ampliﬁ ed 
with a PCR kit（AmpliTaq Gold, Applied Biosystem, 
Foster, CA）in a thermal cycler（Takara PCR Thermal 
Table 1　The speciﬁ c primers and their conditions used to amplify the hBD-2 genes.
The speciﬁ c primers and conditions
SNP positions and primers Sequence Length
－1037,－1029
－938,－925
－914,－876
Forward: primer
Reverse : primer
5’-TGTTTCTCAAACTGCCCTTAG-3’
5’-ATGGGATTGTGACTACATGTG-3’
472bp
－540, Forward: primer
Reverse : primer
5’-AGG CCTGGGTGAACTCTGAGG-3’
5’-GAA AATTCCTCCTATCTTGCA-3’
485bp
－269,－108 Forward: primer
Reverse : primer
5’-ACT CCATTCACACACTGGGTT-3’
5’-AACGAGAAGAGGAGATACAAG-3’
340bp
1765 Forward: primer
Reverse : primer
5’-CGGATTTACTCAAGGCGATAC-3’
5’-TTAGAGATGGCCTGCCCAAAC-3’
405bp
All ampliﬁ cations were done under the same conditions. 
PCR condition : 35 cycles of 94℃ for 45 seconds, 60℃ for 45 seconds and 72℃ for 2 min.
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Cycler MP, Osaka, Japan）according to the manufac-
turer’s instructions.  Sequencing was performed in an 
ABI PRISM 310 Genetic analyzer（Applied Biosystem）
using the BigDye Terminators Cycle Sequencing Ready 
Reaction Kit（Applied Biosystem）according to the 
manufacturer’s instructions.  The SNPs were automati-
cally detected with SeqScape computer software（Ap-
plied Biosystem）.  Allele and genotype frequencies were 
calculated for each site.
Luciferase reporter assay 
　The KB cell line（human oral squamous cell carcino-
ma）was grown in DMEM containing 10% FCS.  Hu-
man β-defensin 2 promoter fragment（－1165/－23）in 
KB cells was cloned by the PCR ampliﬁ cation method. 
The sequences of the primers used for the PCR were as 
follows : forward 5’-GGGGTACCTCTCAAACTGCCCT-
TAGATCGA（including KpnI restricted site）; reverse 
5’-CCCTCGAGCCAGGAGATGAGTCTGGGGAGG（in-
cluding XhoI restricted site）.  The fragment of human 
β-defensin 2 promoter/enhancer was inserted upstream 
of the luciferase gene in the pGL3-Basic vector（Pro-
mega, Madison, WI）.  The Site-direct Mutagenesis Kit
（GeneEditor in vitro Site Direct Mutagenesis system, 
Promega）was used for the preparation of wild and 
variant types of the SNP at position －1029. The prim-
ers used for mutagenesis（bases of the wild and variant 
types underlined）were the following : 5’-CTACTCT-
GGGTTACGGAGGAAGGACAGG（wild-type）, 5’-
CTACTCTG GGTTACGGAAGAAGGACAGG（variant-
type）
　Transfections in KB were performed with EffectenTM
（Qiagen, GmbH, Germany）, and the cells were harvest-
ed at 30 h after transfection with Reporter Lysis buffer
（Promega）.  The luciferase activity of cell lysates was 
then assayed using a Promega Luciferase Assay System
（Promega）in a luminometer（MiniLumat LB9506 
Berthold, Germany）.
Electrophoretic mobility shift assay
　Nuclear protein was extracted from the cell pellets of 
KB cells, according to the method of Dignam et al.14. 
DNA probes for the gel shift assay were obtained from 
the wild and variant types of oligonucleotides.  The 
probes were end-labeled with［γ-32P］ATP by T4 poly-
nucleotide kinase.  Labeled probe was added to the mix-
ture containing 1.5 μg nuclear protein and incubated 
for 30 min at room temperature.  The samples were 
then run on a 5% nondenaturing polyacrylamide gel. 
Gels were dried and 32P radioactivity was visualized by 
BAS 2000（Fuji Film Tokyo, Japan）.  
Results and Discussion 
　By sequencing of hBD-2 genes from 50 unrelated Jap-
anese, we identiﬁ ed 11 SNPs, one in exon 2 and nine in 
the promoter/enhancer region up to －1500bp, as com-
pared with the data in NCBI（AF040153）. The SNP in 
exon 2（＋1765）was synonymous ［CCC（Pre）→CCT
（Pre）］.  This SNP is unlikely to have a signiﬁ cant im-
pact on the biological activity of hBD-2 production.  A 
recent paper reported a nonsynonymous SNP in exon 1 
in Senegalese Africans（allelic frequency ; 3%）15.  How-
ever, no variant in exon 1 was detected in the present 
Japanese population, indicating that there may be a ra-
cial difference.  The paper also showed the SNP at posi-
tion ＋1765, as identiﬁ ed in our study with high allelic 
frequency（21%）15, indicating that this SNP is a com-
mon SNP.  At the －475 and －434 SNPs, all Japanese 
samples showed variant-type CC and GG homozygotes, 
respectively.  Since Jurevic et al. reported these to be 
wild types but not variant15, we omitted those from 
SNPs.  Allele and genotype frequencies are shown in 
Table 2. Variant-type homo frequency and allele fre-
quency at position －269 were more than 50%（54%, 
77%）, indicating that this SNP is wild type in the Japa-
nese population. The SNP has been previously detected 
in North European, Afro-American and Mexican popula-
tions（allele frequencies : 45%, 35% and 30%, respec-
tively）, but not in Middle Eastern populations15.
　Among 9 SNPs in the promoter/enhancer region, only 
the SNP at  position－1029 was located at the tran-
scriptional regulatory element of NF-IL6.  Therefore, we 
carried out a luciferase assay to estimate the effect of 
the variation on the transcriptional activity.  When 
the luciferase vector with the variant-type promoter
（－1029A）was transfected into KB cells, the luciferase 
activity of the cells decreased to below one half of that 
of the cells transfected with wild-type vector（－1029G）
（Fig. 1）.  Furthermore, we carried out electrophoretic 
mobility shift assay targeting－1029 in the NF-IL6 site. 
The nuclear extracts from KB cells bound strongly to 
the wild-type probe, but faintly to the variant-type 
probe（Fig. 2）.  These results suggest that the SNP at 
position－1029 may affect the transcriptional activity 
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of hBD-2.
　Tracheal antimicrobial peptide（TAP）, the ﬁ rst de-
scribed β-defensin, is transcriptionally regulated by the 
cooperative activation of NF-κB and NF-IL6 in re-
sponse to lipopolysaccharide16.  Unlike the TAP gene, 
NF-IL6-binding elements adjacent to individual NF-κB 
sites were deleted in the hBD-2 promoter/enhancer17. 
Thus, inductive expression of the hBD-2 gene is gener-
Table 2　SNPs in β-defensin 2 in a Japanese population and their genotype and allele frequencies.
SNPs in β -defensin 2 in a Japanese population
Promoter Exon 2
Region
SNP Position
NCBI’s report（Variant）
－1037
G（T）
－1029
G（A）
－938
G（A）
－925
C（T）
－914
C（T）
－876
G（A）
－540
C（T）
－269
C（G）
－108
T（C）
1765
T（C）
Wild type homo
Frequency
GG
25/50
0.5
GG
25/50
0.5
GG
49/50
0.98
CC
24/50
0.48
CC
23/50
0.46
GG
19/50
0.38
CC
49/50
0.98
CC
0/50
0
TT
7/50
0.14
TT
21/50
0.42
Hetero type
Frequency
G/T
25/50
0.5
G/A
22/50
0.44
G/A
1/50
0.02
C/T
26/50
0.52
C/T
22/50
0.44
G/A
26/50
0.52
C/T
1/50
0.02
C/G
23/50
0.46
T/C
42/50
0.84
T/C
27/50
0.54
Variant type homo
Frequency
TT
0/50
0
AA
3/50
0.06
AA
0/50
0
TT
0/50
0
TT
5/50
0.1
AA
5/50
0.1
TT
0/50
0
GG
27/50
0.54
CC
1/50
0.02
CC
2/50
0.04
Allele frequency
Allele
Frequency
Allele
Frequency
G
75/100
0.75
T
25/100
0.25
G
72/100
0.72
A
28/100
0.28
G
99/100
0.99
A
1/100
0.01
C
74/100
0.74
T
26/100
0.26
C
68/100
0.68
T
32/100
0.32
G
64/100
0.64
A
36/100
0.36
C
99/100
0.99
T
1/100
0.01
C
23/100
0.23
G
77/100
0.77
T
56/100
0.56
C
44/100
0.44
T
69/100
0.69
C
31/100
0.31
Fig. 2　Electrophoretic mobility shift assay shows the nu-
clear extract from cells bound strongly to the vari-
ant type probe（arrow, G）, but faintly to the wild-
type probe（A）. 
Fig. 1　 Luciferase reporter assay shows the luciferase ac-
tivity of the cells with wild type（－1029G）de-
creases to below one half of that of the cells with 
variant type（－1029A）.
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ally recognized to be regulated by the NF-kB transcrip-
tional factor alone17,18.  However, these reports did not 
focus on the basal promoter/enhancer activity.  hBD-2 
mRNA in oral epithelium and epithelial cell lines are 
detectable even under non-inﬂ ammatory conditions3,4,12. 
Therefore, the basal promoter activity must be neces-
sary for hBD-2 transcription under normal conditions 
without inﬂ ammatory stimulation.  The present data 
suggest the involvement of NF-IL6 in the basal promot-
er activity for hBD-2 transcription.  The Japanese indi-
viduals with －1029G（wild-type）may have lower 
hBD-2 production than those with 1029A（variant-type）. 
This SNP may be useful for a correlation analysis with 
infectious diseases, including periodontal disease.  How-
ever, since the phenotypic contribution of each SNP is 
relatively low in common diseases, a large-scale study 
would be required to enable detection of correlation be-
tween the SNP and disease. 
　In conclusion, we found a new SNP（－1029）in the 
NF-IL6 element of the hBD-2 gene that may inﬂ uence 
hBD-2 expression. The SNP is a candidate for genetic 
variation in susceptibility to infectious disease caused 
by Gram-negative bacteria, such as periodontal disease. 
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